Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Bioscience Reports"
DOI: 10.1042/bsr20200177
Abstract: Abstract Background: The C5 complement inhibitor eculizumab is first-line treatment in atypical hemolytic uremic syndrome (aHUS) going along with a highly increased risk of meningococcal infections. Serogroup B meningococci (MenB) are the most frequently encountered… read more here.
Keywords: uremic syndrome; hemolytic uremic; atypical hemolytic; treatment ... See more keywords